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Cardiovascular disease (CVD) is responsible for the majority of deaths in the developed 
world. Particularly, in patients with chronic kidney disease (CKD), the imbalance of calcium 
and phosphate may lead to the acceleration of both vascular and valve inflammation and 
calcification. One in two patients with CKD are reported as dying from cardiovascular 
causes due to the resulting acceleration in the development of atherosclerosis plaques. 
In addition, CKD patients on hemodialysis are prone to aortic valve calcification and 
often need valve replacement before kidney transplantation. The lysosomal proteases, 
cathepsins, are composed of 11 cysteine members (cathepsin B, C, F, H, K, L, O, S, V, 
W, and Z), as well as serine proteases cathepsin A and G, which cleave peptide bonds 
with serine as the amino acid, and aspartyl proteases D and E, which use an activated 
water molecule bound to aspartate to break peptide substrate. Cysteine proteases, also 
known as thiol proteases, degrade protein via the deprotonation of a thiol and have 
been found to play a significant role in autoimmune disease, atherosclerosis, aortic valve 
calcification, cardiac repair, and cardiomyopathy, operating within extracellular spaces. 
This review sought to evaluate recent findings in this field, highlighting how among 
cathepsins, the inhibition of cathepsin S in particular, could play a significant role in 
diminishing the effects of CVD, especially for patients with CKD.
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iNTRODUCTiON
Cathepsins are lysosomal proteases that breakdown peptide bonds linked to specific amino acids. 
They are known for their key role in protein turnover and significantly contribute to the breakdown 
of the extracellular matrix (ECM). More importantly, cathepsins play a crucial role in various condi-
tions that involve large biological systems such as autoimmune disease, cardiac repair, cardiomyo-
pathy, heart valve disease, and atherosclerosis.
The cathepsin family, cysteinyl, in specific, is known to date to be composed of 11 members 
in humans including cathepsins B, C, F, H, K, L, O, S, V, W, and Z. Cathepsin S is thought to be 
a particularly potent cysteine protease cleaving elastin and generating bioactive elastin peptides, 
leading to the promotion of cardiovascular inflammation and calcification. Beyond boosting inflam-
mation as a part of its own mechanistic process, cathepsin S is also released by smooth muscle cells 
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and macrophages as a systemic response to inflammation in a 
continuous recursive feedback loop.
Vascular inflammation, in particular, is a characteristic fea-
ture in the initiation and progression of atherosclerotic lesions. 
Vascular inflammation that is caused by atherosclerosis is 
described by widespread changes and remodeling of the ECM 
within the arterial wall, both in the degradation of the matrix 
and cellular phenotypic changes. Compounded by chronic 
inflammation and a consistent imbalance in calcium phosphate 
serum levels, patients with chronic kidney disease (CKD) face 
a deleterious feedback loop. This harmful combination further 
accelerates and exacerbates the evolution of atherosclerosis in 
patients with CKD. Studies on atherosclerosis-associated inflam-
matory cytokines have also shown that cathepsin expression and 
activity are amplified within vascular cells (1).
Also affecting patients with CKD, aortic valve calcification is 
highlighted as a major clinical problem in this population, where 
calcification can lead to the progression of aortic valve stenosis. 
Patients with CKD on hemodialysis are prone to developing aor-
tic valve calcification and likely to need valve replacement before 
undergoing kidney transplantation. Of further importance is the 
fact that no current treatment options are available for patients 
with aortic valve stenosis besides valve replacement. Further, 
recent clinical trials have shown no benefit to statin therapy in 
halting the progression of aortic calcification and stenosis (2), 
leaving health professionals and patients with little to no options.
Within this context, one in two patients with CKD are reported 
as dying from increased cardiovascular burden particularly result-
ing from an acceleration in the development of calcification and 
atherosclerotic plaque (3). Hence, the acceleration in the develop-
ment of calcification and atherosclerosis in patients with CKD is 
a leading factor in the simultaneously higher cardiovascular risk, 
the likelihood of developing cardiovascular disease (CVD), and 
ultimately death from cardiovascular causes. Thus, interventions 
that could support in halting or reducing calcification and athero-
sclerosis, especially for patients with CKD is of desperate need.
The inhibition of cathepsin S has been highlighted as a promis-
ing intervention in reducing plaque development and diminish-
ing the effects of CVD, especially for patients with CKD (4). This 
is especially critical considering the lack of treatment options for 
patients with aortic valve calcification that risk progression to 
stenosis and the need for valve replacement. Cathepsin S inhibi-
tion has been shown in evaluations of various cathepsins and 
inhibitors as a promising target. Through this review, we hope 
to better understand the role of cathepsin S in CVD inflamma-
tion and calcification in CKD. More specifically, we will analyze 
inquiries into cathepsin S mechanism of action, its role in various 
processes of inflammation, calcification, and renal disease, and 
identify cathepsin S inhibitors that have been gaged as potential 
and promising treatment targets.
MATeRiALS AND MeTHODS
A review was conducted through a search of the PubMed, 
Medline, the Cochrane Library, and Google databases. The 
following keywords were used: “cathepsin S,” “cardiovascular 
disease,” “chronic renal disease,” “cathepsin S inhibitor,” “renal 
disease,” “calcification,” and “atherosclerosis.” The keywords were 
combined to reach the relevant results.
A review of the titles and abstracts was undertaken to find 
those that matched the keywords of the search. Following the 
review of titles and abstracts, the authors identified six categories 
of interest and organized the articles based on this classification: 
“treatment by cathepsin S inhibitor,” “cathepsin S and renal dis-
ease,” “cathepsin S mechanism,” “cathepsin S and calcification,” 
“cathepsin S and inflammation,” and “miscellaneous.”
The initial review of the databases yielded a total of 41 articles. 
Of those 41, 13 articles were categorized under “cathepsin S 
mechanism,” 12 under “cathepsin S and inflammation,” 7 articles 
were categorized under “treatment by cathepsin S inhibitor,” 6 
were as “cathepsin S and renal disease,” one under the category 
“cathepsin S and calcification,” and two under “miscellaneous,”
Categories Number of 
articles
Publications
Cathepsin S 
mechanism
13 Aikawa et al. (3), Wu et al. (5), Chen et al. 
(6), Moran et al. (7); Pauly et al. (8), Qin et al. 
(9), Lv et al. (10), Pai et al. (11), Cheng et al. 
(1), Sasaki et al. (12), Shi et al. (13), Liuzzo 
et al. (14), and Shi et al. (15)
Cathepsin S and 
inflammation
12 Lafarge et al. (16), Reiser et al. (17), Naour 
et al. (18), Stenvinkel et al. (19), Lutgens 
et al. (20), Rodgers et al. (21), Liu et al. (22), 
Basalyga et al. (23), Go et al. (24), Sukhova 
et al. (25), Jobs et al. (26), and Jobs et al. (27)
Treatment by 
cathepsin S inhibitor
7 Ahmad and Siddiqi (28), Rupanagudi et al. 
(29), Payne et al. (30), Jadhav et al. (31), 
Hilpert et al. (32), Figueiredo et al. (4), and 
Samokhin et al. (33)
Cathepsin S and 
renal disease
6 Huang et al. (34), Steubl et al. (35), Carlsson 
et al. (36), Jobs et al. (37), Smith et al. (38), 
and Inker et al. (39)
Cathepsin S and 
calcification
1 Kumar et al. (40)
Miscellaneous 2 Hewitt et al. (41), and Nadkarni et al. (42)
ReSULTS
Proposed Mechanism of Cathepsin S 
Action
Researchers have sought to understand the role of cathepsin 
S in CVD and systems by evaluating the molecule’s potential 
mechanisms of action. One of the systemic mechanisms recently 
studied is cathepsin S’s role in cardiovascular inflammation and 
calcification especially for patients faced with CKD.
Aikawa et  al. (3) demonstrate through in  vivo experiments 
that elastin degradation induced by cathepsin S accelerates arte-
rial and aortic valve calcification in a CKD model. The findings 
indicate a mechanism of action where cathepsin S contributes 
to the cleavage of the elastin matrix in atherosclerotic lesions 
and inflamed valves, and in the disruption of the tissue layer, 
mesenchymal cells [vascular smooth muscle cells (SMCs) or 
valvular myofibroblasts] proliferate and calcify. The researchers 
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highlight that CKD patients with systemic mineral imbalance 
or hyperphosphatemia experience further acceleration of calci-
fication. The investigators conclude that future interventions in 
calcification-prone individuals should target inflammation and 
phosphate imbalance to reduce the effects of negative feedback 
loops related to elastin degradation and calcification, and incor-
porate the selective inhibition of cathepsin S as a treatment target.
On the other hand, in an arterial medial calcification (AMC), 
a different type of vascular calcification, uremic mouse-model fed 
a high-phosphate diet, Pai et  al. (11) suggest that even though 
elastin degradation is a necessary factor in the cascade leading to 
AMC, it may not be sufficient on its own to induce calcification. 
The researchers indicate that in their findings although elastin 
degradation did occur in uremic mice on a normal phosphate 
diet, they did not develop AMC and thus elastin degradation 
would not be sufficient to induce medial calcification. The 
researchers instead indicate that phenotypic changes and loss of 
vascular SMCs would be both “necessary and sufficient” culprits 
to induce AMC and not elastin degradation alone.
Nevertheless, Simionescu et al. (43) in a study looking at the 
role of fibroblasts in medial vascular calcification find that calci-
fied nodules are formed in the presence of elastin degradation 
products and transforming growth factor (TGF)-β1, especially 
when used together. In this way, the investigators show that elas-
tin degradation peptides, highly active biologic products known 
as matrikines, can induce calcification of mesenchymal cells 
in vitro. These findings suggest that elastin degradation could in 
fact induce calcification.
Additionally, in a murine model with cathepsin S inhibitor 
E64d, Chen et  al. (6) find that cathepsin S plays a part in the 
signaling of TGF-β1, myofibroblast differentiation, and ECM 
creation and modulation in myocardial infarction (MI). The 
researchers describe how cathepsin S participates in regulating 
scar formation in the infarcted myocardium and preserve left 
ventricular function after experimentally induced MI. Further, 
Shi et al. (13) find that growth of new blood vessels is abnormal 
during wound repair in a cathepsin S-deficient mouse model, 
despite regular endothelial and fibroblast growth factor levels. 
Their results show that when cathepsin S activity is inhibited, 
the formation of microtubules is reduced, suggesting an essential 
role of cathepsin S in ECM degradation during vessel formation 
and repair.
Sasaki et  al. (12) suggest that cathepsin S derived from 
macrophages are involved in the mechanisms that lead to the 
vulnerability of atherosclerotic plaque with increased levels of 
cathepsin S found in plaque. Knowing of angiotensin II as a player 
in vascular homeostasis, the researchers elucidate to angiotensin 
II type 1 receptor (AT1) blocker, olmesartan, as maintaining the 
stability of plaques, while simultaneously suppressing cathepsin 
S and macrophage activity. The authors then suggest the use of 
olmesartan as a treatment intervention in reducing cardiovascu-
lar consequences.
Cheng et  al. (1) in a comprehensive review of the literature 
on the contributions of cathepsins in atherosclerosis-based 
vascular disease find strong evidence implicating cathepsins in 
related mechanisms of action. The researchers highlight that 
feasibility studies looking at cathepsins as diagnostic tools have 
shown promising results in the use of cathepsins S and L, and the 
endogenous inhibitor cystatin C as biomarkers for determining 
coronary artery disease and the formation of aneurysms.
In abdominal aortic aneurysm (AAA), often described for 
its wide degradation of the aortic wall matrix, remodeling and 
further rupturing of the wall, Qin et al. (9) in a murine model, 
provide evidence of cathepsin S’s role in the formation of AAA 
and suggest cathepsin S as a new therapeutic target for prevent-
ing AAAs in humans. Additionally, Lv et  al. (10) test plasma 
samples of 476 male patients with AAA and 200 age-matched 
male controls as part of an ongoing randomized trial of more than 
50,000 men aged 65–74 in Denmark. The researchers find in this 
population a correlation between plasma cathepsin S, cystatin 
C, aortic diameter, and the lowest ankle–brachial index. Their 
results suggest these parameters could be used as biomarkers 
for assessing arterial diseases and AAA, highlighting that more 
advanced cases of AAA would contain higher levels of cathepsin 
S in the AAA lesions as well as in circulation.
Important to highlight is that investigators suggest future 
interventions in calcification-prone individuals target inflamma-
tion and phosphate imbalance, together with the selective inhibi-
tion of cathepsin S as a treatment target (3, 11). Additionally, 
after review of evidence on cathepsins in atherosclerosis-based 
vascular disease, and feasibility studies of cathepsins as potential 
diagnostic tools, Cheng et al. (1) conclude that cathepsins S and L 
and endogenous inhibitor cystatin C could be used as biomarkers 
in determining the existence of coronary artery disease and the 
formation of aneurysms clinically.
Cathepsin S inhibition
Other researchers have also inquired about various cathepsin 
S inhibitors as treatment for cardiovascular disorders. Ahmad 
and Siddiqi (28) perform simulations of the molecule’s docking 
and dynamics to better understand the molecular mechanism of 
action of the cathepsin S inhibitor RO5444101. The researchers 
demonstrated a selectivity of this inhibitor for cathepsin S rather 
than cathepsin L1/L, cathepsin L2/V, and cathepsin K, claim-
ing that the cathepsin S compound is more stable and involves 
more protein–molecule interactions. Figueiredo et al. (4) found 
that the systemic inhibition of cathepsin S by the compound 
RO5444101 attenuated the progression of atherosclerotic lesions 
in high-fat high-cholesterol fed apolipoprotein E-deficient 
nephrectomized mice. The authors conclude that the cathepsin S 
inhibitor accomplishes this through the simultaneous reduction 
in immunoreactivity of cathepsin S, elastin degradation, plaque 
size, macrophage accumulation, growth differentiation factor-15, 
and alkaline phosphatase activity. These results suggest a potential 
role of cathepsin S in the treatment of atherosclerosis in patients 
with CKD by possibly reducing the progression of atherosclerotic 
lesions.
In addition, Rupanagudi et al. (29), in an experimental mouse 
model of systemic lupus erythematosus and lupus nephritis, find 
that cathepsin S inhibition by RO5461111 shows therapeutic ben-
efits. The inhibition of cathepsin S significantly reduced the exces-
sive autoimmune response found in this disease presentation by 
blocking the assembly of major histocompatibility complex class 
II molecules in T and B cells. The investigators suggest that the 
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inhibition of cathepsin S protects in the progression of lupus 
nephritis and could be useful in other autoimmune diseases.
Further, Payne et  al. (30) assess the tolerability of safety of 
the cathepsin S inhibitor, LY3000328 in a phase 1, placebo-
controlled study. The researchers use a single escalating dose 
ranging from 1 to 300  mg with 21 healthy male volunteers 
and find that the compound was quickly cleared from plasma 
within 12–13 h. They also found that the compound produced 
a transient decrease in plasma cathepsin S activity followed by 
a more prolonged increase in plasma cathepsin S mass. With 
this, the authors suggest that future studies include longer post-
dose measurements to assess activity and impact. Additionally, 
Jadhav et  al. (31), using an experimental CaCl2-induced AAA 
mouse model, report that cathepsin inhibitor LY3000328 binds 
to subsites without forming covalent interactions. The research-
ers report that among the tested compounds, LY3000328 was 
selected for clinical development, and may provide a new clinical 
treatment for AAA.
Hilpert et al. (32) further account the development of “Potent 
and Selective Cathepsin S Inhibitors Containing Different Central 
Cyclic Scaffolds.” In a transgenic mouse model of antigen presen-
tation (DO10.11), the authors show a reduction in the production 
of the immune system cytokine interleukin (IL)-2 by one of the 
cathepsin S inhibitors studied through dose-dependent studies. 
Finally, Samokhin et al. (33) investigate the effects of a specific 
cathepsin S inhibitor in atherosclerotic plaque progression in an 
apoe–deficient mice fed a high-fat diet. The inhibition of cathep-
sin S showed protection of atherosclerotic activity. The research-
ers indicated that this protection is depicted in the decrease of 
atherosclerotic plaque size, the number of elastin lamina breaks, 
the numbers of plaque macrophages and buried fibrous caps. To 
highlight is that the researchers found a 36 and 68% reduction 
in plaque size, 60 and 75% in elastin breaks in males vs. females, 
respectively, and caphepsin S-deficient mice showed a decrease of 
close to 90%. These results further demonstrate the potential of 
cathepsin S inhibition as therapy.
The described research has looked at various cathepsin S 
inhibitors such as RO5444101, RO5461111, LY3000328, among 
others, to understand mechanism, evaluate clearance from 
plasma, test toxicity, and investigate whether these inhibitors may 
be good options as clinical treatment targets. Researchers have 
also demonstrated how the inhibition of cathepsin S decreased 
the size of atherosclerotic plaques showing cathepsin S’s potential 
role as a therapeutic option.
Cathepsin S and inflammation
In terms of the association between cathepsin S and inflammation, 
Jobs et al. (27) investigate in a community-based cohort of elderly 
men, whether there is an existing association between serum 
levels of cathepsin S and markers of inflammation mediated by 
cytokines. The authors then find that higher levels of cathepsin 
S were associated with higher C-reactive protein and higher 
serum IL-6 levels, both inflammatory markers. This association 
was persistent at a reassessment after 7  years from the initial 
baseline levels acquired. The researchers find that an interplay 
between cathepsin S and inflammation markers are present even 
in normal-weight individuals.
Further, in two independent cohorts of elderly men and 
women, Jobs et al. (26) sought to evaluate associations between 
circulating cathepsin S levels and mortality, considering that 
experimental studies have suggested the connection between 
cathepsin S activity and the development of CVD through the 
increase in the formation of and destabilization of atherosclerotic 
plaque. The researchers find that higher serum cathepsin S lev-
els were associated with an increased mortality risk in a linear 
regression model. Further, in one of the independent cohorts, the 
researchers found that cathepsin S was independently associated 
with CVD and cancer, and suggest future studies should evaluate 
cathepsin S’s potential clinical utility.
Lafarge et al. (16), in a review of current literature, attempt to 
understand further the links between obesity, metabolic disease, 
and CVD. Knowing that adipose tissue produces a number of 
pro-inflammatory factors, the group find that the gene encoding 
cathepsin S is one of the most unregulated in the adipose tissue 
of obese subjects. Further, the researchers also add that cathepsin 
S is positively correlated with body mass index. To conclude, they 
highlight that future inquiries are needed to establish whether 
cathepsin inhibitors could be beneficial in reducing metabolic 
and cardiovascular comorbidities in the obese.
Additionally, Naour et al. (18) in a prospective study with two 
independent cohorts of obese females find that when looking at 
cathepsin S, L, and K, that obese subjects have a twofold increase 
in cathepsin S in adipose tissue, as compared to normal-weight 
control subjects, and an increased rate of cathepsin S release in 
adipose tissue. However, it remains unknown whether the inhibi-
tion of cathepsin S in obesity can reduce cardiovascular risk or 
improve the metabolic status of obese patients.
Cathepsin S and Renal Disease
Aikawa et  al. (3) demonstrate that CKD accelerates cathepsin 
S-induced atherosclerotic and aortic valve inflammation and 
calcification in apolipoprotein-deficient mice. On the connection 
between cathepsin S and renal disease, a study by Steubl et  al. 
(35) finds that as glomerular filtration rates decline, cathepsin 
S and markers of inflammation-related endothelial dysfunction 
increase. This indicates that cathepsin S activity increases with 
CKD progression, suggesting that cathepsin S may be a thera-
peutic target to prevent cardiovascular complications in CKD. 
Huang et al. (34) reveal a role of cathepsin S in epidermal growth 
factor receptors (EGFR) signaling regulation. EGFR expression 
has been reported as increased in various tumors of the blad-
der, colon, ovarian, and kidney. Thus, the researchers argue for 
the clinical evaluation of cathepsin S and EGFR tyrosine kinase 
inhibitors in combination.
Further, Carlsson et al. (36) in a longitudinal cohort study of 
207 patients undergoing hemodialysis found that cathepsin S and 
L were associated with receptors for tumor necrosis factors. The 
researchers conclude that the high levels of endostatin, cathepsins 
S and L, and their associations with tumor necrosis factors war-
rant further studies within this population exploring mortality, 
and pathways involved in end-stage renal disease. Additionally, 
Smith et  al. (38) analyze in 200 patients with stages 3 and 4 
CKD and a subgroup of 65 patients, elastin-derived peptides, 
their endogenous inhibitors, and aortic pulse wave velocity 
FigURe 1 | Acceleration of cardiovascular calcification through cathepsin S-associated elastin degradation in a CKD milieu. This figure is reproduced from Aikawa 
et al. (3), with the author’s permission.
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over a 36-month period. The researchers find that higher serum 
elastin-derived peptide levels were independently associated with 
increased all-cause mortality.
Cathepsin S and Calcification
Cardiovascular calcification is described as a disease resulting 
from the disarray of an individual’s mineral metabolism where 
the buildup of minerals such as calcium and phosphate can lead 
to the vessel hardening and disruption of normal physiological 
processes (3). At the population level, a growing burden of epide-
miologic factors such as aging, hypercholesterolemia, and renal 
insufficiency have led to an increased prevalence of arterial and 
aortic valve calcification.
Further, of important clinical concern has been the progres-
sion of calcification to even more debilitating conditions such as 
plaque rupture or aortic valve stenosis. Of additional concern is 
the fact that there are currently no treatment options available for 
reducing or avoiding these advanced conditions, beyond valve 
replacement (2).
In a study looking at the role of fibroblasts in medial vascular 
calcification, Simionescu et al. (43) find that calcified nodules are 
formed in the presence of elastin degradation products and TGF-
β1. The researchers show that elastin degradation peptides can 
induce calcification of mesenchymal cells in vitro. These findings 
suggest that elastin degradation could in fact induce calcification 
of vascular SMCs and valvular myofibroblasts and thus mediate 
calcification.
A few other studies have also suggested that in the presence of 
mineral discrepancy, cathepsin S can participate in cardiovascular 
calcification where extracellular vesicles could then serve as loci 
for microcalcifications (44–49). The above described studies as 
well as studies by Aikawa et al. (3) and Figueiredo et al. (4) suggest 
the role of cathepsin S in cardiovascular calcification associated 
with mineral imbalance found in diabetes and CKD.
DiSCUSSiON
Multiple studies have indicated that cathepsin S activity increases 
with the progression of CKD and have highlighted cathepsin S 
inhibition as a therapeutic target in the prevention of cardiovascu-
lar complications for this patient population. Patients with CKD 
face a deleterious feedback loop composed and compounded 
by chronic inflammation and a consistent imbalance in calcium 
phosphate serum levels. This harmful combination accelerates 
and exacerbates the evolution of atherosclerosis in patients with 
CKD. In atherosclerotic lesions, cathepsin S, one of the most 
potent mammalian elastases, is highly expressed. Macrophages 
are then set in action as an essential part of the innate immune 
response, further releasing high levels of cathepsin S.
With the progression of kidney failure in patients with CKD, 
uremia and uremic toxins, produced during the deterioration of 
multiple biological functions could lead to the apoptosis and early 
damage of vessel wall. Extracellular vesicles could then serve as 
loci for microcalcifications (44–49). However, in the face of altered 
mineral metabolism, this could also lead to a set of pathological 
reactions including calcification of medial SMCs and elastin. 
Damaged kidneys and abnormal hormone levels in CKD cause 
calcium and phosphorus levels in the blood to be out of balance. 
This disruption and potential damage more commonly occurs in 
people with kidney failure receiving hemodialysis, who are more 
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prone to aortic valve calcification and stenosis, needing valve 
replacement before undergoing kidney transplantation. This in 
itself could lead to increased cardiovascular mortality for those 
with CKD. Elevations in serum calcium and phosphate levels, 
such as what occurs with patients under dialysis with CKD, or as 
a result of calcium–phosphate binder use, or vitamin D treatment 
(11), can lead to devastating circumstances, and is even more 
critical for this patient population.
Cathepsin S, through the cleavage of elastin and generation 
of bioactive elastin peptides, boosts cardiovascular inflammation 
and calcification. Changes in mineral imbalance, along with 
the elevation of cathepsin S, may lead to the transformation of 
mesenchymal cells, including vascular SMCs and interstitial cells 
to an osteochondrogenic, or stiffened phenotype, thus accelerat-
ing calcification even further (Figure 1) (3). Through its role in 
cardiovascular calcification in its association with calcium and 
phosphate imbalance, cathepsin S is thus involved in the feedback 
loop between these two biological processes predominant in CKD.
Therefore, as demonstrated in these investigations, cathepsin S 
may play a deleterious role and be the culprit for the initiation of 
calcification. This transition to a calcified state could be induced 
either via increased elastolytic activity and production of elastic 
peptides that directly induce smooth muscle cell or interstitial cell 
differentiation toward osteogenic bone-like phenotype, or via the 
induced release of extracellular vesicles or apoptotic bodies that 
could serve as loci resulting in dystrophic calcification (50).
Aortic valve calcification through the hardening of the valve 
reduces the movement of aortic valve leaflets, impacting and 
weakening cardiac function. Because mature aortic valves have 
an elastin-rich, multilayered structure and can develop inflamma-
tory lesions that recapitulate features of atherosclerotic plaques, 
researchers have proposed that similar mechanisms of cathepsin 
S-associated elastin degradation contribute to the development of 
calcific aortic valve disease (3).
Facing this deleterious feedback loop compounded by chronic 
inflammation and a consistent imbalance in calcium–phosphate 
serum levels, patients with CKD are found in a harmful combina-
tion that would further accelerate and exacerbate the evolution of 
cardiovascular calcification (51, 52). Therefore, researchers have 
suggested that the early diagnosis and intervention toward inter-
fering the progression of aortic valve calcification could provide 
immense clinical benefits.
The studies evaluated in this review have provided further 
evidence of the potential of the inhibition of cathepsin S as inter-
vention toward reducing plaque development and diminishing 
the effects of CVD especially for patients with CKD.
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